GIPC2

GIPC2 is a PDZ-domain scaffolding adaptor of the GIPC family that couples membrane receptors to intracellular signaling and transcriptional outputs, acting in contexts ranging from cancer progression to stem-cell differentiation (PMID:11836570, PMID:35347223, PMID:41500998). Through its central PDZ domain it engages distinct partners to produce opposing outcomes: it binds the WNT co-receptor Fzd7 to activate WNT-β-catenin signaling and drive prostate cancer metastasis (PMID:35347223), and it binds pyruvate kinase M2 (PKM2) to promote PKM2 nuclear translocation and SREBP1 activation, driving adipogenic differentiation of mesenchymal stem cells (PMID:41500998). In a separate tumor-suppressive role, GIPC2 interacts with the nucleoprotein NONO to drive p27 transcription via a shared GGCC box on the p27 promoter, suppressing MAPK/ERK and HIF-1α signaling and chromaffin-cell proliferation downstream of RET and SDHB (PMID:33947839). GIPC2 expression is silenced by promoter methylation in AML cells, and its restoration triggers apoptosis through inhibition of PI3K/AKT signaling (PMID:37212125). The Xenopus ortholog binds the IGF receptor and functions in IGF-PI3K signaling required for pronephros development (PMID:22689378). GIPC2 protein is also present in tumor-derived exosomes, where it stimulates cancer cell adhesion, invasion, and migration (PMID:35347223).

1. 2002 Medium

   Establishing GIPC2 as a distinct PDZ-domain protein defined the molecular scaffold framework through which all later functions would be interpreted.

   Evidence cDNA cloning, sequence and exon-intron structural analysis identifying GIPC2 as the second GIPC family member with a central PDZ domain

   PMID:11836570

   Open questions at the time

   • No functional partner or pathway assigned at this stage
   • PDZ-domain binding specificity not yet defined
2. 2012 Medium

   Linking the Xenopus ortholog to the IGF receptor placed GIPC2 in receptor-coupled PI3K signaling and gave it a developmental role for the first time.

   Evidence Morpholino knockdown with pronephros phenotype, constitutively active PI3K rescue, and Co-IP of gipc2 with IGFR in Xenopus laevis

   PMID:22689378

   Open questions at the time

   • Mechanism connecting IGFR binding to PI3K activation not resolved
   • Relevance to mammalian GIPC2 function untested
   • Role of the eif6 interaction unclear
3. 2021 High

   Identifying the GIPC2-NONO interaction and a shared p27 promoter element revealed a transcriptional, tumor-suppressive arm of GIPC2 acting downstream of oncogenic RET/SDHB lesions.

   Evidence Reciprocal Co-IP, promoter reporter/ChIP at the p27 GGCC box, ERK/HIF-1α Western blotting, and RET/SDHB epistasis in primary rat chromaffin and PC12 cells with xenograft readout

   PMID:33947839

   Open questions at the time

   • How GIPC2, a PDZ adaptor, reaches the p27 promoter is unexplained
   • Direct DNA binding versus NONO-mediated recruitment not distinguished
   • Generality beyond pheochromocytoma/paraganglioma untested
4. 2022 High

   Demonstrating direct PDZ-domain binding to Fzd7 assigned GIPC2 a pro-metastatic, WNT-activating role, in apparent contrast to its tumor-suppressive function in chromaffin cells.

   Evidence Co-IP defining PDZ-Fzd7 interaction, siRNA/shRNA loss-of-function, in vitro invasion/migration assays, and in vivo prostate cancer xenograft metastasis models

   PMID:35347223

   Open questions at the time

   • Reconciliation of pro-metastatic versus tumor-suppressive roles across tissues unresolved
   • Whether WNT and NONO/p27 arms operate in the same cells unknown
5. 2022 Medium

   Detecting GIPC2 in tumor-derived exosomes extended its action beyond the cell of origin to intercellular promotion of invasive behavior.

   Evidence Exosome isolation with proteomic identification and adhesion/invasion/migration assays following exosome treatment

   PMID:35347223

   Open questions at the time

   • Mechanism of GIPC2 loading into exosomes unknown
   • Receptor/target on recipient cells not identified
6. 2023 Medium

   Showing methylation-dependent silencing and apoptosis upon restoration linked GIPC2 expression control to PI3K/AKT-mediated cell survival in leukemia.

   Evidence Bisulfite sequencing, decitabine restoration, CCK-8 viability, and PI3K/AKT Western blotting with overexpression in HL-60 AML cells

   PMID:37212125

   Open questions at the time

   • Direct molecular link between GIPC2 and PI3K/AKT components not defined
   • Whether PDZ-domain interactions mediate this effect untested
7. 2026 High

   Identifying PKM2 as a PDZ-domain partner and tracing the GIPC2-PKM2-SREBP1 axis established a metabolic/differentiation role and clarified how GIPC2 controls nuclear translocation of a partner.

   Evidence Co-IP defining PDZ-PKM2 interaction, nuclear fractionation/imaging of PKM2 translocation, SREBP1 reporter/Western blotting, and gain/loss-of-function in UC-MSCs with adipogenic differentiation readout

   PMID:41500998

   Open questions at the time

   • How a cytoplasmic-membrane adaptor promotes nuclear import of PKM2 is mechanistically unresolved
   • Relationship to GIPC2's cancer-associated roles unknown

• It remains unknown how a single PDZ adaptor produces opposing tumor-promoting and tumor-suppressive outcomes, and what determines which partner (Fzd7, NONO, PKM2, IGFR) GIPC2 engages in a given cell.
• No structural basis for partner selectivity
• No unifying model across tissues
• Endogenous subcellular localization of GIPC2 not directly mapped